
|Videos|June 16, 2011
Dr. Wolchok Describes Candidates for Ipilimumab
Author(s)Jedd D. Wolchok, MD, PhD
Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes Candidates for Ipilimumab
Advertisement
Jedd D. Wolchok, MD, PhD From Memorial Sloan-Kettering Cancer Center describes candidates for ipilimumab.
Dr. Wolchok says many melanoma patients are candidates for ipilimumab, if they have unresectable stage III or stage IV disease. Patients with melanoma that has spread to a distant organ or that has spread to local lymph nodes but can't be surgically removed are patients who, by the current US label, are eligible. The patients who doctors should be careful in using this drug with have a history of autoimmune disease.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5




































